Abstract released: interim results from IPH5201 Phase 2 to be presented at AACR 2026

Lyon, France, April 17th, 2026 – OREGA Biotech reports that the AACR 2026 abstract reporting interim results from the Phase 2 MATISSE trial of IPH5201 plus durvalumab and platinum-based chemotherapy in patients with resectable early-stage NSCLC has been published.

Summary of the abstract

Perioperative PD-(L)1 inhibitors combined with chemotherapy are now standard for resectable early-stage NSCLC, but further improvements in pathological complete response (pCR) and survival are still needed. IPH5201 aims to enhance antitumour immunity by reducing immunosuppressive adenosine and increasing ATP levels.

Among 40 patients with stage II–IIIA NSCLC, the treatment showed a favourable safety profile and achieved a pCR rate of 27.5% (all), rising to 35.7% in PD-L1 ≥1% and 50% in PD-L1 ≥50% patients — comparing favourably with the 17.2%, 21.2% and 27.5% reported for durvalumab + chemotherapy in the AEGEAN study (Heymach, 2023). Biomarker analyses confirmed CD39 target engagement and suggested a link between CD39+ tumour cell density and response. These results support the continuation of the study with the recruitment of PD-L1 ≥1% patients.

Presentation details

• Session CTPL04 – Advances in Immunotherapy
• CT231 – Dual CD39 and PD-L1 inhibition: interim results from the Phase 2 MATISSE trial of IPH5201 plus durvalumab and platinum-based chemotherapy in patients with resectable NSCLC
• April 21, 2026, 10:45–11:00 AM · Hall H, Convention Center
• Presenter: Pr. Fabrice Barlesi, CEO of Institut Gustave Roussy

About the MATISSE trial

MATISSE (NCT05742607) is a Phase 2 multicentre single-arm study of neoadjuvant and adjuvant IPH5201 with durvalumab and chemotherapy in treatment-naïve patients with resectable early-stage NSCLC. Primary objectives are antitumour activity based on pCR, and safety.